title: Immunotherapy for advanced prostate cancer: a novel treatment option to improve survival.
abstract: Prostate cancer is the second leading cause of cancer death in men in the United States. Novel immunotherapies are being investigated to improve survival in patients with advanced disease. Sipuleucel-T (PROVENGE), the first autologous cellular immunotherapy approved by the U. S. Food and Drug Administration, improves survival in men with asymptomatic or minimally symptomatic metastatic castration-resistant (hormone refractory) prostate cancer.
authors: MediMedia USA.
authors: Steven R
authors: SR
authors: Peskin
mesh_terms: D000367:Age Factors; D001859:Bone Neoplasms / Q000453:epidemiology / Q000556:secondary; D019496:Cancer Vaccines / Q000627:therapeutic use*; D003365:Costs and Cost Analysis; D006801:Humans; D007167:Immunotherapy / Q000379:methods / Q000639:trends; D008297:Male; D009364:Neoplasm Recurrence, Local / Q000453:epidemiology; D011471:Prostatic Neoplasms / Q000188:drug therapy* / Q000191:economics / Q000401:mortality / Q000473:pathology; D012307:Risk Factors; D012720:Severity of Illness Index; D016019:Survival Analysis; D014020:Tissue Extracts / Q000627:therapeutic use*; D014481:United States / Q000453:epidemiology
chemical_list: D019496:Cancer Vaccines; D014020:Tissue Extracts; C511774:sipuleucel-T